Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 9:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 6,600 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Neutropenia, Sarcoma
Interventions: voriconazole; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years to 11 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 7
States / cities: Orange, California • San Diego, California • Bethesda, Maryland + 4 more

Conditions: Heart Failure
Interventions: OPTIMIZER Smart System; Device
Lead sponsor: Impulse Dynamics; Industry
Eligibility: 18 Years and older
Enrollment: 620 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 90
States / cities: Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 69 more

Conditions: Advanced or Metastatic Non-small Cell Lung Cancer
Interventions: TAS-114, S-1; Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 6
States / cities: Loma Linda, California • Gainesville, Florida • Cleveland, Ohio + 3 more

Conditions: Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, High Grade B-cell Lymphoma (HGBCL), Primary Mediastinal B-cell Lymphoma (PMBCL), Transformed Lymphoma, Central Nervous System Lymphoma, Mantle Cell Lymphoma (MCL), Richter Transformation, Transplant-ineligible 2nd Line DLBCL
Interventions: zamtocabtagene autoleucel (MB-CART2019.1), Cyclophosphamide, Fludarabine, Bendamustine; Biological · Drug
Lead sponsor: Miltenyi Biomedicine GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 30
States / cities: Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 26 more

Conditions: RSV Immunization
Interventions: RSVt vaccine, Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine, Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine, Hepatitis B vaccine, Streptococcus pneumoniae vaccine, Rotavirus vaccine, Measles, mumps, and rubella vaccine, Varicella virus vaccine, Placebo; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months to 12 Months
Enrollment: 2,226 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 66
States / cities: Birmingham, Alabama • Grand Bay, Alabama • Mobile, Alabama + 55 more

Conditions: Advanced Solid Tumors
Interventions: DN1508052-01; Drug
Lead sponsor: Shanghai De Novo Pharmatech Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 3
States / cities: La Jolla, California • St Louis, Missouri • Seattle, Washington

Conditions: Hip Fractures, Femoral Neck Fractures
Interventions: Total hip arthroplasty, Hemi-arthroplasty; Device
Lead sponsor: McMaster University; Other
Eligibility: 50 Years and older
Enrollment: 1,495 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Head and Neck Cancer
Interventions: IL-12; Biological
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2000
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Hemorrhoids, Internal
Interventions: HET Bipolar System; Device
Lead sponsor: Medtronic - MITG; Industry
Eligibility: 21 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Metastatic Colorectal Cancer
Interventions: Pembrolizumab, Binimetinib, Oxaliplatin, Leucovorin, 5-Fluorouracil [5-FU], Irinotecan; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 10
States / cities: Duarte, California • Aurora, Colorado • New Haven, Connecticut + 7 more

Conditions: Hormone Refractory Prostate Cancer
Interventions: LBH589; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 5
States / cities: Boston, Massachusetts • St Louis, Missouri • Las Vegas, Nevada + 2 more

Conditions: Vertebral Cervical Fusion Syndrome, Degenerative Disc Disease
Interventions: CervicalStim bone growth stimulator; Device
Lead sponsor: Orthofix Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Johnstown, Colorado

Conditions: Healthy Volunteer, Cystic Fibrosis
Interventions: PTI-801, Placebo, PTI-808; Drug
Lead sponsor: Proteostasis Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 171 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 33
States / cities: Birmingham, Alabama • Anchorage, Alaska • Stanford, California + 28 more

Conditions: Provoked Vestibulodynia, Secondary Provoked Vestibulodynia, Vulvodynia, Vulvary Pain Disorders, Neuroproliferative Vestibulodynia, Mast Cell-mediated Neuroinflammation, Instertional Dyspareunia
Interventions: Ketotifen Fumarate 0.25% Cream, Placebo (Vehicle Cream); Drug
Lead sponsor: Center for Vulvovaginal Disorders; Other
Eligibility: 18 Years and older · Female only
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Tampa, Florida • New York, New York

Conditions: Vulvovaginal Atrophy, Menopause, Dyspareunia, Painful Intercourse
Interventions: Estradiol, Placebo; Drug
Lead sponsor: TherapeuticsMD; Industry
Eligibility: 40 Years to 75 Years · Female only
Enrollment: 764 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 100
States / cities: Huntsville, Alabama • Montgomery, Alabama • Mesa, Arizona + 85 more

Conditions: Cushing's Disease, Acromegaly
Interventions: Pasireotide s.c., Sitagliptin, Liraglutide, Insulin, Pasireotide LAR, Metformin; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 15
States / cities: Multiple Locations, California • Torrance, California • Ventura, California + 10 more

Conditions: Osteoarthritis of the Knee
Interventions: honeybee venom (Apitoxin (Korea) Apitox (USA)); Drug
Lead sponsor: Apimeds, Inc.; Industry
Eligibility: 35 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 4
States / cities: Pinellas Park, Florida • Chicago, Illinois • Columbus, Ohio + 1 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Canakinumab, Metformin, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 556 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 18
States / cities: Phoenix, Arizona • La Jolla, California • Los Gatos, California + 15 more

Conditions: Endocrine Tumors
Interventions: lanreotide (Autogel formulation), Placebo; Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 8
States / cities: Los Angeles, California • Iowa City, Iowa • Baltimore, Maryland + 5 more

Conditions: Depressive Disorder, Major
Interventions: SUVN-911, Placebo; Drug
Lead sponsor: Suven Life Sciences Limited; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Progressive Supranuclear Palsy
Interventions: Placebo, ABBV-8E12; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 40 Years and older
Enrollment: 378 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 27
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Beverly Hills, California + 22 more

Conditions: Alzheimer Disease
Interventions: COR388, Placebo; Drug
Lead sponsor: Cortexyme Inc.; Industry
Eligibility: 55 Years to 80 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 3
States / cities: San Diego, California • Orlando, Florida • Cincinnati, Ohio

Conditions: Central Neuropathic Pain, Multiple Sclerosis
Interventions: AVP-923-45, AVP-923-30, AVP-923-20, Placebo; Drug
Lead sponsor: Avanir Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 44
States / cities: Cullman, Alabama • Phoenix, Arizona • Berkeley, California + 40 more

Conditions: Brain Neoplasms
Interventions: MPC-6827; Drug
Lead sponsor: Myrexis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy

Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy

A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1

DALY II USA/ MB-CART2019.1 for DLBCL

Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers

A Study to Evaluate the Safety, Tolerability of DN1508052-01 in Advanced Solid Tumors

Comparing Total Hip Arthroplasty and Hemi-Arthroplasty on Secondary Procedures and Quality of Life in Adults With Displaced Hip Fractures

Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer

Safety and Efficacy Study of HET Bipolar System for Treatment of Stage I and Stage II Hemorrhoids

Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651)

Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone

Study Using the CervicalStim Device Following Cervical Fusion

Study Assessing the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and Pharmacokinetics of PTI-801 in Subjects With Cystic Fibrosis

Topical Ketotifen 0.25% for Secondary Vestibulodynia

Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women

Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly

Apitox, Honeybee Venom Treatment for Osteoarthritis Pain and Inflammation

Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients

Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-911 in Healthy Subjects

A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP)

A Multiple Ascending Dose Study of COR388

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Multiple Dose Study of MPC-6827 in Subjects With Refractory Brain Metastases